 NEW YORK, Nov. 02, 2020 GLOBE NEWSWIRE -- Royalty Pharma plc Nasdaq: RPRX announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.s cystic fibrosis CF treatments owned by the Cystic Fibrosis Foundation. The agreement includes an upfront payment of 575 million and a potential milestone payment of 75 million. 